HOME >> BIOLOGY >> NEWS
Multi-species genome comparison sheds new light on evolutionary processes, cancer mutations

BETHESDA, Md., Thurs., July 21, 2005 An international team that includes researchers from the National Human Genome Research Institute (NHGRI), part of the National Institutes of Health (NIH), has discovered that mammalian chromosomes have evolved by breaking at specific sites rather than randomly as long thought and that many of the breakage hotspots are also involved in human cancer.

In a study published in the July 22 issue of the journal Science, a team of 25 scientists from the United States, France and Singapore compared the organization of the chromosomes of eight mammalian species: human, mouse, rat, cow, pig, dog, cat and horse. Using sophisticated computer software to align and compare the mammals' genetic material, or genomes, the team determined that chromosomes tend to break in the same places as species evolve, resulting in rearrangements of their DNA. Prior to the discovery of these breakage hotspots, the prevailing view among scientists was that such rearrangements occurred at random locations.

"This study shows the tremendous power of using multi-species genome comparisons to understand evolutionary processes, including those with potential relevance to human disease," said NHGRI Scientific Director Eric D. Green, M.D., Ph.D. "The dog genome map generated by NHGRI researchers and their collaborators played a key role in these new analyses. Furthermore, the team took full advantage of the wealth of human, mouse and rat genome sequence data generated by the recently completed Human Genome Project."

Chromosomes are the threadlike "packages" of DNA located in the nucleus of each cell. When cells divide, a chromosome occasionally breaks and the fragment can get stuck onto another chromosome. In addition, fragments may break off from two different chromosomes and swap places.

Chromosomal breakages, also referred to as translocations, are thought to be important in terms of evolution. When chromosomes break in egg or sperm c
'"/>

Contact: Leslie Saint-Julien
lsaintj@mail.nih.gov
301-402-0911
NIH/National Human Genome Research Institute
21-Jul-2005


Page: 1 2 3

Related biology news :

1. Multi-species herbivore outbreak follows El Nio drought in Panama
2. Unravelling new complexity in the genome
3. One species, many genomes
4. First genome-wide study of infectious disease opens new avenues for HIV treatment, vaccines
5. Charting ever-changing genomes
6. Neutral evolution has helped shape our genome
7. Sea anemone genome provides new view of our multi-celled ancestors
8. Cloning the male genome may help infertile men
9. Mutating the entire genome
10. Exploring the dark matter of the genome
11. New findings challenge established views on human genome

Post Your Comments:
(Date:3/31/2015)... , March 31, 2015  Elephant Talk Communications Corp. ... global provider of Software Defined Network Architecture (ET Software ... total revenue of approximately $20.4 million for the year ... $19.5 million for the year ended December 31, 2013. ... the Company had completed its multi-year transition away from ...
(Date:3/31/2015)... NEW YORK , March 31, 2015   ... announced the launch of the Post-Surgical Pain Management TRACKER, ... data products tracking usage trends in the medical device ... monthly access to data including treatment volumes, market share, ... manage the pain associated with joint surgery. ...
(Date:3/30/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/lc9bnl/global_gesture ... Gesture Recognition Market in Automotive Sector 2014-2018" report ... Global Gesture Recognition market in Automotive Sector to grow ... Gesture recognition is the ability of a ... an individual. Gesture recognition technology can be 2D-based or ...
Breaking Biology News(10 mins):Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2
(Date:3/31/2015)... Diasome Pharmaceuticals, Inc. ( http://www.diasome.com ) has ... United States patent has recently been allowed for the ... Entitled “Lipid Construct for Delivery of Insulin to a ... to the use of Diasome’s proprietary Hepatocyte Directed Vesicles ... more effectively reach the liver’s metabolic cells, called hepatocytes. ...
(Date:3/30/2015)... NC (PRWEB) March 30, 2015 ... are pleased to announce the formation of VaxCorps, ... research centers specializing in the conduct of vaccine ... VaxCorps clinical sites have successfully conducted over ... experience in seasonal and pandemic influenza as well ...
(Date:3/30/2015)... March 30, 2015  NuGene International, Inc. ("NuGene") ... NuGene BioPharma, Inc. has added another internationally recognized ... Guan is an internationally recognized researcher in bio-inspired ... education at Peking University, China ... the University of North Carolina, Chapel Hill. Following ...
(Date:3/30/2015)... March 30, 2015 CASI Pharmaceuticals, Inc. (Nasdaq: ... acquisition, development and commercialization of innovative therapeutics addressing cancer ... with a commercial focus on China ... Administration (CFDA) has approved the Company,s application to conduct ... cell carcinoma (OCCC) patients for its proprietary drug candidate ...
Breaking Biology Technology:Diasome Pharmaceuticals, Inc. Announces Notice of Allowance from US PTO for Liver Targeting System for Insulin 2PMG Research announces formation of VaxCorps with two industry-leading vaccine site networks 2UCI Professor Zhibin Guan Joins NuGene Advisory Board 2UCI Professor Zhibin Guan Joins NuGene Advisory Board 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 4CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 5
Cached News: